首页 > 最新文献

Journal of Heart and Lung Transplantation最新文献

英文 中文
Considerations in Interpreting Pulmonary Artery Pulsatility Index and Right Ventricle -Pulmonary Arterial Coupling in Left Ventricular Assist Device Candidates. 在左心室辅助装置候选者中解释肺动脉脉搏指数和右心室-肺动脉耦合的考虑。
IF 6 1区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2026-02-04 DOI: 10.1016/j.healun.2026.01.031
Alina Nicoara, Mihai V Podgoreanu
{"title":"Considerations in Interpreting Pulmonary Artery Pulsatility Index and Right Ventricle -Pulmonary Arterial Coupling in Left Ventricular Assist Device Candidates.","authors":"Alina Nicoara, Mihai V Podgoreanu","doi":"10.1016/j.healun.2026.01.031","DOIUrl":"https://doi.org/10.1016/j.healun.2026.01.031","url":null,"abstract":"","PeriodicalId":15900,"journal":{"name":"Journal of Heart and Lung Transplantation","volume":" ","pages":""},"PeriodicalIF":6.0,"publicationDate":"2026-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146132088","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Editorial: 10-year data on oral selexipag: long-term survival, safety, and dosing insights in pulmonary arterial hypertension from the GRIPHON study and its open-label extension - big data-small impact. 编辑:口服selexipag的10年数据:来自GRIPHON研究及其开放标签扩展的肺动脉高压的长期生存、安全性和剂量见解-大数据-小影响。
IF 6 1区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2026-02-04 DOI: 10.1016/j.healun.2026.01.030
Irene M Lang
{"title":"Editorial: 10-year data on oral selexipag: long-term survival, safety, and dosing insights in pulmonary arterial hypertension from the GRIPHON study and its open-label extension - big data-small impact.","authors":"Irene M Lang","doi":"10.1016/j.healun.2026.01.030","DOIUrl":"https://doi.org/10.1016/j.healun.2026.01.030","url":null,"abstract":"","PeriodicalId":15900,"journal":{"name":"Journal of Heart and Lung Transplantation","volume":" ","pages":""},"PeriodicalIF":6.0,"publicationDate":"2026-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146132021","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Combined heart and other organ transplants in Spain: insights from the COMBI study. 西班牙的心脏和其他器官联合移植:来自COMBI研究的见解。
IF 6 1区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2026-02-04 DOI: 10.1016/j.healun.2026.01.027
Toshihiro Nakayama, Kazunari Sasaki
{"title":"Combined heart and other organ transplants in Spain: insights from the COMBI study.","authors":"Toshihiro Nakayama, Kazunari Sasaki","doi":"10.1016/j.healun.2026.01.027","DOIUrl":"https://doi.org/10.1016/j.healun.2026.01.027","url":null,"abstract":"","PeriodicalId":15900,"journal":{"name":"Journal of Heart and Lung Transplantation","volume":" ","pages":""},"PeriodicalIF":6.0,"publicationDate":"2026-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146132058","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Redefining Risk Assessment with Absolute dd-cfDNA in Lung Transplantation. 用绝对dd-cfDNA重新定义肺移植风险评估。
IF 6 1区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2026-02-04 DOI: 10.1016/j.healun.2026.01.029
Kentaro Noda, Pablo G Sanchez
{"title":"Redefining Risk Assessment with Absolute dd-cfDNA in Lung Transplantation.","authors":"Kentaro Noda, Pablo G Sanchez","doi":"10.1016/j.healun.2026.01.029","DOIUrl":"https://doi.org/10.1016/j.healun.2026.01.029","url":null,"abstract":"","PeriodicalId":15900,"journal":{"name":"Journal of Heart and Lung Transplantation","volume":" ","pages":""},"PeriodicalIF":6.0,"publicationDate":"2026-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146132074","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
ISHLT Consensus Statement on Short Telomere Syndrome and Lung Transplantation: Authors’ Perspective 短端粒综合征和肺移植:作者的观点
IF 6 1区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2026-01-16 DOI: 10.1016/j.healun.2025.10.027
Andrew M. Courtwright , John A. Mackintosh , Jonathan K. Alder , Christine Kim Garcia , Antoine Froidure , Erin Lowery , Don Hayes Jr. , Pali Shah , Quentin Philippot , Raphael Borie , John R. Greenland , Hannah Mannem , Mark E. Snyder , Merel Hellemons , Laurie D. Snyder , John McDyer
{"title":"ISHLT Consensus Statement on Short Telomere Syndrome and Lung Transplantation: Authors’ Perspective","authors":"Andrew M. Courtwright , John A. Mackintosh , Jonathan K. Alder , Christine Kim Garcia , Antoine Froidure , Erin Lowery , Don Hayes Jr. , Pali Shah , Quentin Philippot , Raphael Borie , John R. Greenland , Hannah Mannem , Mark E. Snyder , Merel Hellemons , Laurie D. Snyder , John McDyer","doi":"10.1016/j.healun.2025.10.027","DOIUrl":"10.1016/j.healun.2025.10.027","url":null,"abstract":"","PeriodicalId":15900,"journal":{"name":"Journal of Heart and Lung Transplantation","volume":"45 2","pages":"Pages 163-167"},"PeriodicalIF":6.0,"publicationDate":"2026-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145981999","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Information for Readers 读者资讯
IF 6 1区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2026-01-16 DOI: 10.1016/S1053-2498(25)02502-1
{"title":"Information for Readers","authors":"","doi":"10.1016/S1053-2498(25)02502-1","DOIUrl":"10.1016/S1053-2498(25)02502-1","url":null,"abstract":"","PeriodicalId":15900,"journal":{"name":"Journal of Heart and Lung Transplantation","volume":"45 2","pages":"Page A2"},"PeriodicalIF":6.0,"publicationDate":"2026-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145982002","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Considerations for Endpoints in Lung Transplant Clinical Trials: Perspective on the ISHLT Consensus Statement 肺移植临床试验终点的考虑:从ISHLT共识声明的角度看
IF 6 1区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2026-01-16 DOI: 10.1016/j.healun.2025.09.016
John R. Greenland MD, PhD , Michael Perch MD , Kieran Halloran MD, MSc , Deborah J. Levine MD , Eric D. Morrell MD, MA , Anna Reed MBChB , Ciara M. Shaver MD, PhD , Jonathan P. Singer MD, MS , Stuart C. Sweet MD, PhD , Robin Vos MD, PhD , Shambhu Aryal MD, FCCP , Nicholas Avdimiretz MD, FRCPC , Fay Burrows Bpharm , Daniel Calabrese MD , Fiorella Calabrese MD , Silvia Campos PhD , Michael Combs MD, MS , Marc de Perrot MD, MSc, FRCSC , Göran Dellgren MD, PhD , Joshua M. Diamond MD, MS , Jamie L. Todd MD, MHS
{"title":"Considerations for Endpoints in Lung Transplant Clinical Trials: Perspective on the ISHLT Consensus Statement","authors":"John R. Greenland MD, PhD , Michael Perch MD , Kieran Halloran MD, MSc , Deborah J. Levine MD , Eric D. Morrell MD, MA , Anna Reed MBChB , Ciara M. Shaver MD, PhD , Jonathan P. Singer MD, MS , Stuart C. Sweet MD, PhD , Robin Vos MD, PhD , Shambhu Aryal MD, FCCP , Nicholas Avdimiretz MD, FRCPC , Fay Burrows Bpharm , Daniel Calabrese MD , Fiorella Calabrese MD , Silvia Campos PhD , Michael Combs MD, MS , Marc de Perrot MD, MSc, FRCSC , Göran Dellgren MD, PhD , Joshua M. Diamond MD, MS , Jamie L. Todd MD, MHS","doi":"10.1016/j.healun.2025.09.016","DOIUrl":"10.1016/j.healun.2025.09.016","url":null,"abstract":"","PeriodicalId":15900,"journal":{"name":"Journal of Heart and Lung Transplantation","volume":"45 2","pages":"Pages 168-171"},"PeriodicalIF":6.0,"publicationDate":"2026-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145982004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Letter to Carnicelli et al. outcomes with Impella CP in acute myocardial infarction vs heart failure cardiogenic shock 致Carnicelli等人的信。Impella CP治疗急性心肌梗死与心力衰竭心源性休克的结果
IF 6 1区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2026-01-16 DOI: 10.1016/j.healun.2025.09.007
Jacob E. Møller , Norman Mangner , Vasileios Panoulas , Christian Hassager
{"title":"Letter to Carnicelli et al. outcomes with Impella CP in acute myocardial infarction vs heart failure cardiogenic shock","authors":"Jacob E. Møller , Norman Mangner , Vasileios Panoulas , Christian Hassager","doi":"10.1016/j.healun.2025.09.007","DOIUrl":"10.1016/j.healun.2025.09.007","url":null,"abstract":"","PeriodicalId":15900,"journal":{"name":"Journal of Heart and Lung Transplantation","volume":"45 2","pages":"Page 312"},"PeriodicalIF":6.0,"publicationDate":"2026-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145981960","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
ISHLT Consensus Statement on Short Telomere Syndrome and Lung Transplantation 短端粒综合征与肺移植的ISHLT共识声明。
IF 6 1区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2026-01-08 DOI: 10.1016/j.healun.2025.10.028
Andrew M. Courtwright MD, PhD , John A. Mackintosh , Jonathan K. Alder , Christine Kim Garcia , Antoine Froidure , Erin Lowery , Don Hayes Jr. , Shah Pali , Quentin Philippot , Raphael Borie , John R. Greenland , Hannah Mannem , Mark E. Snyder , Merel Hellemons , Laurie D. Snyder , John McDyer
Motivated by growing evidence that the presence of critically shortened telomeres influences interstitial lung disease (ILD) trajectories and is associated with extrapulmonary conditions relevant to lung transplant candidacy and post-transplant complications, this Consensus Statement aims to address gaps in the evaluation and management of patients with short telomere syndrome (STS). These considerations reflect the work of an international Writing Committee with expertise in STS and are grounded in current literature and expert consensus. The need for this document arises from the recognition that STS is an underdiagnosed contributor to ILD, and that its presence introduces complexities that require dedicated, multidisciplinary attention in the transplant setting.
越来越多的证据表明,严重缩短的端粒会影响间质性肺病(ILD)的发展轨迹,并与肺移植候选资格和移植后并发症相关的肺外条件有关,因此,本共识声明旨在解决短端粒综合征(STS)患者评估和管理方面的空白。这些考虑反映了具有STS专业知识的国际写作委员会的工作,并以当前文献和专家共识为基础。由于认识到STS是ILD的一个未被诊断的因素,并且它的存在引入了复杂性,需要在移植环境中进行专门的多学科关注,因此需要编写此文件。
{"title":"ISHLT Consensus Statement on Short Telomere Syndrome and Lung Transplantation","authors":"Andrew M. Courtwright MD, PhD ,&nbsp;John A. Mackintosh ,&nbsp;Jonathan K. Alder ,&nbsp;Christine Kim Garcia ,&nbsp;Antoine Froidure ,&nbsp;Erin Lowery ,&nbsp;Don Hayes Jr. ,&nbsp;Shah Pali ,&nbsp;Quentin Philippot ,&nbsp;Raphael Borie ,&nbsp;John R. Greenland ,&nbsp;Hannah Mannem ,&nbsp;Mark E. Snyder ,&nbsp;Merel Hellemons ,&nbsp;Laurie D. Snyder ,&nbsp;John McDyer","doi":"10.1016/j.healun.2025.10.028","DOIUrl":"10.1016/j.healun.2025.10.028","url":null,"abstract":"<div><div>Motivated by growing evidence that the presence of critically shortened telomeres influences interstitial lung disease (ILD) trajectories and is associated with extrapulmonary conditions relevant to lung transplant candidacy and post-transplant complications, this Consensus Statement aims to address gaps in the evaluation and management of patients with short telomere syndrome (STS). These considerations reflect the work of an international Writing Committee with expertise in STS and are grounded in current literature and expert consensus. The need for this document arises from the recognition that STS is an underdiagnosed contributor to ILD, and that its presence introduces complexities that require dedicated, multidisciplinary attention in the transplant setting.</div></div>","PeriodicalId":15900,"journal":{"name":"Journal of Heart and Lung Transplantation","volume":"45 2","pages":"Pages e83-e103"},"PeriodicalIF":6.0,"publicationDate":"2026-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145933618","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Venopulmonary extracorporeal life support: An Extracorporeal Life Support Organization registry analysis. 静脉体外生命支持:另一个注册表分析。
IF 6 1区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2026-01-06 DOI: 10.1016/j.healun.2025.12.024
Luca Baldetti, Domenico Pontillo, Massimo Capoccia, Mariusz Kowalewski, Joseph E Tonna, Mikael Broman, Steven A Conrad, Justyna Swol, Anna Mara Scandroglio, J Michael Brewer, Marc O Maybauer, Roberto Lorusso

Background: There is a paucity of data informing on the current use, adverse events, outcomes, and prognostic drivers for patients receiving venopulmonary extracorporeal life support (VP ECLS). We aimed to provide a contemporary, large sample size study to describe the real-world outcomes of adults supported with VP ECLS across different clinical conditions.

Methods: We queried the Extracorporeal Life Support Organization Registry to retrieve all adult patients who received VP ECLS as the first support modality from July 2020 to July 2024. Study population was grouped according to hospital death outcome and to the diagnosis leading to VP ECLS use. Adverse outcomes are reported according to the diagnosis leading to VP ECLS use. A time-to-event Cox regression model was applied to identify predictors of death.

Results: A total of 838 patients [32.3% females; age 8 (46, 67) years] were included. Patients were treated for heart failure/cardiogenic shock (HF/CS) in 54.4%, for acute respiratory failure/acute respiratory distress syndrome (ARF/ARDS) in 26.6%, for post-cardiotomy shock in 6.7%, for acute coronary syndrome/ischemic heart disease in 5.3%, for valvular heart disease/complications of intracardiac devices in 4.2%, and for pulmonary embolism in 2.9%. Most common adverse events included continuous renal replacement therapy (CRRT) use or acute kidney injury (37.4%), infections (35.4%), cardiac arrhythmias (13.5%), surgical site bleeding (12.1%), gastrointestinal (GI) bleeding (6.1%). Complications were more common in non-survivors and patterns of complications differed among diagnosis groups. The Kaplan-Meier estimated 60-day survival was 49.3 (45.3, 53.1)%. Age (HRadj 1.15 for 5 years increase; 95%CI 1.11, 1.20; p < 0.001), female sex (HRadj 1.40; 95%CI 1.12, 1.76; p = 0.003), body mass index (HRadj 1.02 for 3 kg/m2 increase; 95%CI 1.01, 1.04; p < 0.018), CRRT use prior VP ECLS cannulation (HRadj 1.44; 95%CI 1.11, 1.86; p < 0.006) were independent predictors of death.

Conclusions: In this large Extracorporeal Life Support Organization registry analysis, VP ECLS was chiefly used for HF/CS and ARF/ARDS. Hospital outcomes, complications, and survival differed according to the diagnosis leading to VP ECLS use. Younger age, male sex, lower BMI, and no CRRT use prior to VP ECLS cannulation confer a lower risk of death and provide targets for future research and potential domains for clinical improvement.

背景:目前关于接受静脉肺体外生命支持(VP ECLS)患者的使用、不良事件、结局和预后驱动因素的数据缺乏。我们的目的是提供一项当代的、大样本量的研究,以描述在不同临床条件下支持VP ECLS的成人的现实结果。方法:我们查询了体外生命支持组织(ELSO)注册表,检索了2020年7月至2024年7月期间接受VP ECLS作为第一支持方式的所有成年患者。研究人群根据医院死亡结局和导致VP ECLS使用的诊断进行分组。不良后果报告根据初步诊断导致VP ECLS的使用。采用时间-事件Cox回归模型确定死亡预测因子。结果:共838例患者,其中女性32.3%;年龄为8岁(46,67岁)。因心力衰竭/心源性休克(HF/CS)治疗的患者占54.4%,因急性呼吸衰竭/急性呼吸窘迫综合征(ARF/ARDS)治疗的患者占26.6%,因开心术后休克治疗的患者占6.7%,因急性冠状动脉综合征/缺血性心脏病治疗的患者占5.3%,因瓣膜病/心脏内装置并发症治疗的患者占4.2%,因肺栓塞治疗的患者占2.9%。最常见的不良事件包括持续肾替代治疗(CRRT)或急性肾损伤(37.4%)、感染(35.4%)、心律失常(13.5%)、手术部位出血(12.1%)、胃肠道出血(6.1%)。并发症在非幸存者中更为常见,并发症的模式在不同的诊断组中有所不同。Kaplan-Meier估计60天死亡率为49.3%(45.3%,53.1%)。年龄(HRadj 1.15,增加5年;95%CI 1.11, 1.20; padj 1.40; 95%CI 1.12, 1.76; p=0.003), BMI (HRadj 1.02,增加3 kg/m2; 95%CI 1.01, 1.04; padj 1.44; 95%CI 1.11, 1.86; p=0.003)结论:在这项大型ELSO注册分析中,VP ECLS主要用于HF/CS和ARF/ARDS。根据诊断导致使用VP ECLS的住院结果、并发症和生存率不同。较年轻的年龄、男性、较低的BMI和在VP ECLS插管前未使用CRRT赋予较低的死亡风险,并为未来的研究和临床改善的潜在领域提供了目标。
{"title":"Venopulmonary extracorporeal life support: An Extracorporeal Life Support Organization registry analysis.","authors":"Luca Baldetti, Domenico Pontillo, Massimo Capoccia, Mariusz Kowalewski, Joseph E Tonna, Mikael Broman, Steven A Conrad, Justyna Swol, Anna Mara Scandroglio, J Michael Brewer, Marc O Maybauer, Roberto Lorusso","doi":"10.1016/j.healun.2025.12.024","DOIUrl":"10.1016/j.healun.2025.12.024","url":null,"abstract":"<p><strong>Background: </strong>There is a paucity of data informing on the current use, adverse events, outcomes, and prognostic drivers for patients receiving venopulmonary extracorporeal life support (VP ECLS). We aimed to provide a contemporary, large sample size study to describe the real-world outcomes of adults supported with VP ECLS across different clinical conditions.</p><p><strong>Methods: </strong>We queried the Extracorporeal Life Support Organization Registry to retrieve all adult patients who received VP ECLS as the first support modality from July 2020 to July 2024. Study population was grouped according to hospital death outcome and to the diagnosis leading to VP ECLS use. Adverse outcomes are reported according to the diagnosis leading to VP ECLS use. A time-to-event Cox regression model was applied to identify predictors of death.</p><p><strong>Results: </strong>A total of 838 patients [32.3% females; age 8 (46, 67) years] were included. Patients were treated for heart failure/cardiogenic shock (HF/CS) in 54.4%, for acute respiratory failure/acute respiratory distress syndrome (ARF/ARDS) in 26.6%, for post-cardiotomy shock in 6.7%, for acute coronary syndrome/ischemic heart disease in 5.3%, for valvular heart disease/complications of intracardiac devices in 4.2%, and for pulmonary embolism in 2.9%. Most common adverse events included continuous renal replacement therapy (CRRT) use or acute kidney injury (37.4%), infections (35.4%), cardiac arrhythmias (13.5%), surgical site bleeding (12.1%), gastrointestinal (GI) bleeding (6.1%). Complications were more common in non-survivors and patterns of complications differed among diagnosis groups. The Kaplan-Meier estimated 60-day survival was 49.3 (45.3, 53.1)%. Age (HR<sub>adj</sub> 1.15 for 5 years increase; 95%CI 1.11, 1.20; p < 0.001), female sex (HR<sub>adj</sub> 1.40; 95%CI 1.12, 1.76; p = 0.003), body mass index (HR<sub>adj</sub> 1.02 for 3 kg/m<sup>2</sup> increase; 95%CI 1.01, 1.04; p < 0.018), CRRT use prior VP ECLS cannulation (HR<sub>adj</sub> 1.44; 95%CI 1.11, 1.86; p < 0.006) were independent predictors of death.</p><p><strong>Conclusions: </strong>In this large Extracorporeal Life Support Organization registry analysis, VP ECLS was chiefly used for HF/CS and ARF/ARDS. Hospital outcomes, complications, and survival differed according to the diagnosis leading to VP ECLS use. Younger age, male sex, lower BMI, and no CRRT use prior to VP ECLS cannulation confer a lower risk of death and provide targets for future research and potential domains for clinical improvement.</p>","PeriodicalId":15900,"journal":{"name":"Journal of Heart and Lung Transplantation","volume":" ","pages":""},"PeriodicalIF":6.0,"publicationDate":"2026-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145933633","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of Heart and Lung Transplantation
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1